Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DURAGESIC-75 vs ANEXSIA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fentanyl is a potent opioid agonist primarily at the mu-opioid receptor, exerting its analgesic effects by mimicking endogenous endorphins and enkephalins to activate G-protein-coupled inwardly rectifying potassium channels, leading to hyperpolarization and reduced neuronal excitability in pain pathways.
ANEXSIA is a combination of hydrocodone and acetaminophen. Hydrocodone is an opioid agonist that binds to mu-opioid receptors in the central nervous system, altering pain perception and emotional response to pain. Acetaminophen's analgesic mechanism is not fully understood but involves inhibition of COX enzymes in the CNS and modulation of descending serotonergic pathways.
Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate (FDA-approved for opioid-tolerant patients only).
Relief of moderate to moderately severe pain
Adults: Apply one 75 mcg/hr transdermal patch every 72 hours. Start with lower dose in opioid-naive patients.
50-100 mg orally every 4-6 hours as needed; maximum 400 mg/day.
22-25 hours after removal of patch; increased in elderly, hepatic/renal impairment
Terminal elimination half-life is 4-6 hours in adults with normal renal function; prolonged to 12-24 hours in severe renal impairment (Cr Cl <30 m L/min).
Primarily metabolized via CYP3A4 in the liver and intestinal mucosa to norfentanyl and other minor metabolites; undergoes extensive first-pass metabolism.
Hydrocodone is metabolized via CYP2D6 and CYP3A4 to hydromorphone and norhydrocodone. Acetaminophen is primarily metabolized via hepatic glucuronidation and sulfation; a minor pathway via CYP2E1 produces NAPQI, which is detoxified by glutathione.
Renal (75% as metabolites, <10% unchanged), fecal (25%)
Approximately 70% renal (unchanged drug and metabolites), 20% biliary/fecal, 10% other.
90-95% bound to alpha-1-acid glycoprotein and albumin
Approximately 95% bound to plasma albumin and alpha-1-acid glycoprotein.
6-7 L/kg, indicating extensive tissue distribution
0.2-0.4 L/kg, indicating limited extravascular distribution primarily confined to plasma and interstitial fluid.
Fentanyl transdermal: 50-65% of patch content absorbed into systemic circulation
Oral: 80-90%; Intramuscular: 90-100%; Rectal: 70-80%.
GFR 30-89 m L/min: No adjustment. GFR <30 m L/min: Reduce dose by 50% and monitor.
GFR 30-89 m L/min: no adjustment; GFR 15-29 m L/min: 50% dose reduction; GFR <15 m L/min: avoid use.
Child-Pugh Class A: No adjustment. Class B: Reduce dose by 25-50%. Class C: Avoid use.
Child-Pugh A: no adjustment; Child-Pugh B: 50% dose reduction; Child-Pugh C: avoid use.
Children ≥2 years: 12.5-25 mcg/hr initial, titrate based on need; max dose 25 mcg/hr for opioid-naive.
1-2 mg/kg/dose orally every 6 hours; maximum 6 mg/kg/day.
Initial dose reduction of 25-50%; titrate cautiously; avoid in frail elderly.
Initiate at 25 mg every 6 hours; increase cautiously; monitor renal function.
Risk of respiratory depression that may result in death; ensure proper patient selection, dosing, and monitoring. Avoid use in opioid non-tolerant patients. Accidental exposure can be fatal. Concomitant use with CNS depressants increases risk. Risk of abuse, misuse, addiction, and diversion. Neonatal opioid withdrawal syndrome with prolonged use during pregnancy. Risk of life-threatening respiratory depression from CYP3A4 inhibitors or discontinuation of CYP3A4 inducers.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; hepatotoxicity from acetaminophen.
Risk of life-threatening respiratory depression, especially in elderly, cachectic, or debilitated patients,Risk of opioid-induced hyperalgesia,Risk of serotonin syndrome with serotonergic drugs,Hypersensitivity reactions including anaphylaxis,Risk of withdrawal with abrupt discontinuation,Hepatic or renal impairment may alter pharmacokinetics,Avoid in patients with significant respiratory depression, acute or severe bronchial asthma, or known or suspected paralytic ileus,May impair mental or physical abilities needed for driving or operating machinery,Use with caution in patients with head injuries, increased intracranial pressure, or convulsive disorders,Application site reactions or adhesive-related injuries
Risk of respiratory depression, especially in elderly or debilitated patients; adrenal insufficiency; severe hypotension; seizures; opioid-induced hyperalgesia; acetaminophen hepatotoxicity (avoid exceeding 4 g/day); serotonin syndrome if used with serotonergic agents.
Opioid non-tolerant patients (not established for acute pain or short-term use),Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment,Known or suspected gastrointestinal obstruction, including paralytic ileus,Hypersensitivity to fentanyl or any component of the system (e.g., adhesives),Concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of such therapy
Hypersensitivity to hydrocodone or acetaminophen; significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting; known or suspected GI obstruction; severe hepatic impairment; concomitant use of MAOIs or within 14 days.
No significant food interactions. Grapefruit juice may increase fentanyl levels via CYP3A4 inhibition; caution with high intake. Avoid alcohol due to additive CNS depression.
Avoid alcohol; may increase risk of hepatotoxicity and GI bleeding. Limit caffeine intake from coffee, tea, cola, or energy drinks due to added caffeine content. High-fat meals may delay absorption; take on empty stomach for faster onset if tolerated.
Fetal risk cannot be ruled out. In first trimester, no clear evidence of major malformations from opioid analgesics, but data limited. Second and third trimesters: chronic use may cause fetal opioid dependence, neonatal abstinence syndrome (NAS) postpartum. Use during labor may cause respiratory depression in neonate. Risk of preterm birth and low birth weight with prolonged use.
First trimester: Data are limited; no increased risk of major malformations reported in small studies. Second and third trimesters: Associated with premature closure of the ductus arteriosus and oligohydramnios due to fetal renal effects; avoid use after 30 weeks gestation.
Fentanyl is excreted in breast milk. M/P ratio approximately 0.4. Breastfeeding is generally not recommended during Duragesic-75 use due to risk of infant sedation and respiratory depression. If used, monitor infant for unusual sleepiness, difficulty breathing, or poor feeding. Alternative analgesics are preferred.
Excreted into breast milk in low concentrations (M/P ratio not established). Not recommended during breastfeeding due to potential for adverse effects in the infant, including renal impairment and gastrointestinal bleeding.
No specific dose adjustments are established for Duragesic-75 in pregnancy. Fentanyl pharmacokinetics may be altered due to increased plasma volume, renal clearance, and hepatic metabolism; however, transdermal absorption may be inconsistent. Use lowest effective dose for shortest duration. Consider alternative opioids with more pregnancy data. Taper dose before delivery to reduce NAS risk.
Dose adjustment not generally required; however, due to increased renal clearance in pregnancy, shortened dosing intervals may be necessary for sustained efficacy. Use lowest effective dose for shortest duration.
DURAGESIC-75 delivers fentanyl at 75 mcg/hour transdermally. Do not use in opioid-naive patients due to risk of fatal respiratory depression. Apply to non-irritated, non-hairy skin on upper torso or upper arm. Avoid heat sources (heating pads, hot tubs) as heat increases absorption. Onset ~12-24 hours; peak effect ~24-72 hours. Remove old patch before applying new; rotate sites. Do not cut or damage the patch. Monitor for serotonin syndrome if used with serotonergic drugs. For breakthrough pain, use immediate-release opioids not additional fentanyl patches.
ANEXSIA is a combination analgesic containing paracetamol, ibuprofen, and caffeine. It is contraindicated in patients with active peptic ulcer disease, severe hepatic impairment, or hypersensitivity to NSAIDs. Avoid concurrent use with other NSAIDs or paracetamol-containing products. Monitor renal function in elderly or dehydrated patients. Caffeine may exacerbate anxiety or insomnia.
Apply the patch to a flat, non-hairy area of the upper body or arm. Do not use on skin that is irritated, cut, or scarred.,Do not expose the patch to direct heat sources like heating pads, electric blankets, hot tubs, or sunbathing—this can cause a dangerous overdose.,Wash hands after handling the patch. Dispose of used patches by folding sticky sides together and flushing down toilet per FDA guidelines.,Remove the old patch and apply the new patch to a different skin site every 72 hours (3 days). Rotate sites to avoid skin irritation.,Do not cut, chew, or damage the patch—this can lead to rapid release of fentanyl and fatal overdose.,Store patches in a secure place away from children and pets. Accidental exposure can be fatal.,Common side effects include nausea, vomiting, constipation, dizziness, and drowsiness. Report severe drowsiness, confusion, difficulty breathing, or signs of an allergic reaction.,Avoid alcohol, other opioids, benzodiazepines, and sedatives as they increase risk of respiratory depression.,Do not stop using this medication suddenly; taper with prescriber to avoid withdrawal symptoms.,Seek emergency care for symptoms of overdose: slow or shallow breathing, extreme drowsiness, or unresponsiveness.
Do not exceed recommended dose; overdosage of paracetamol can cause liver damage.,Take with food or milk to reduce gastrointestinal upset.,Avoid alcohol while taking this medication to reduce risk of liver toxicity and GI bleeding.,Discontinue use and consult if signs of allergic reaction, GI bleeding, or liver problems occur.,Caffeine may cause nervousness, insomnia, or increased heart rate; limit caffeine-containing foods and beverages.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DURAGESIC-75 vs ANEXSIA, answered by our medical review team.
DURAGESIC-75 is a Opioid Analgesic that works by Fentanyl is a potent opioid agonist primarily at the mu-opioid receptor, exerting its analgesic effects by mimicking endogenous endorphins and enkephalins to activate G-protein-coupled inwardly rectifying potassium channels, leading to hyperpolarization and reduced neuronal excitability in pain pathways.. ANEXSIA is a Opioid Analgesic Combination that works by ANEXSIA is a combination of hydrocodone and acetaminophen. Hydrocodone is an opioid agonist that binds to mu-opioid receptors in the central nervous system, altering pain perception and emotional response to pain. Acetaminophen's analgesic mechanism is not fully understood but involves inhibition of COX enzymes in the CNS and modulation of descending serotonergic pathways.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DURAGESIC-75 and ANEXSIA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DURAGESIC-75 is: Adults: Apply one 75 mcg/hr transdermal patch every 72 hours. Start with lower dose in opioid-naive patients.. The standard adult dose of ANEXSIA is: 50-100 mg orally every 4-6 hours as needed; maximum 400 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DURAGESIC-75 and ANEXSIA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DURAGESIC-75 is classified as Category C. Fetal risk cannot be ruled out. In first trimester, no clear evidence of major malformations from opioid analgesics, but data limited. Second and third trimesters: chronic use may . ANEXSIA is classified as Category C. First trimester: Data are limited; no increased risk of major malformations reported in small studies. Second and third trimesters: Associated with premature closure of the ductus . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.